Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 15/20 | 0.77 |
| ▸ | RXRB | P28702 | 14/20 | 0.77 |
| ▸ | RXRG | P48443 | 11/20 | 0.77 |
| ▸ | NR4A2 | P43354 | 6/20 | 0.77 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.65 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.65 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.65 |
| ▸ | NR4A1 | P22736 | 2/20 | 0.65 |
| ▸ | NR4A3 | Q92570 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.65 |
| ▸ | C5 | P01031 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.65 |
| ▸ | DRD2 | P14416 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5733040 | 1.00 | RXRA (0.77) | RXRARXRBRXRGNR4A2PTGS1 | |
| SCHEMBL8547300 | 0.97 | RXRA (0.78) | RXRARXRBRXRGNR4A2PTGS1 | |
| SCHEMBL8550151 | 0.96 | RXRA (0.76) | RXRARXRBRXRGNR4A2PTGS1 | |
| SCHEMBL5732939 | 0.93 | RXRA (0.76) | RXRARXRBRXRGNR4A2PTGS1 | |
| SCHEMBL5732078 | 0.93 | RXRA (0.76) | RXRARXRBRXRGNR4A2PTGS1 | |
| SCHEMBL7501065 | 0.91 | RXRA (0.63) | RXRARXRBRXRGNR4A2PTGS1 | |
| SCHEMBL7506581 | 0.89 | RXRA (0.77) | RXRARXRBRXRGNR4A2PTGS1 | |
| SCHEMBL5732773 | 0.89 | RXRA (0.77) | RXRARXRBRXRGNR4A2PTGS1 | |
| SCHEMBL7507422 | 0.88 | RXRA (0.60) | RXRARXRBRXRGNR4A2PTGS1 | |
| SCHEMBL7508237 | 0.88 | RXRA (0.60) | RXRARXRBRXRGNR4A2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060251689-A1 | Treatment or prevention of pruritus | ASTION DEVELOPMENT A/S | 2006-11-09 | — | — | US | claimed |
| US-20060229347-A1 | Treatment of eczemas | ASTION DEVELOPMENT A/S | 2006-10-12 | — | — | US | claimed |
| WO-2006102898-A2 | OXAPROZIN OR A CLOSELY RELATED COMPOUND FOR THE TREATMENT OF ECZEMA | ASTION PHARMA A/S (DK) | 2006-10-05 | — | — | WO | claimed |
| WO-2006102899-A2 | OXAPROZIN OR CLOSELY RELATED COMPOUND FOR THE TREATMENT AND PREVENTION OF | ASTION PHARMA A/S (DK) | 2006-10-05 | — | — | WO | claimed |
| WO-2006102900-A1 | DERMATOLOGICAL COMPOSITIONS AND SALTS FOR THE TREATMENT OF DERMATOLOGICAL DISEASES | ASTION PHARMA A/S (DK) | 2006-10-05 | — | — | WO | claimed |
| US-20060222671-A1 | Dermatological compositions and salts for the treatment of dermatological diseases | ASTION DEVELOPMENT A/S | 2006-10-05 | — | — | US | claimed |
| EP-1707200-A1 | Dermatological compositions comprising oxaprozin or a closely related compound for the treatment of dermatological diseases | Astion Development A/S (DK) | 2006-10-04 | — | — | EP | claimed |
| EP-1707199-A1 | Oxaprozin or closely related compound for the treatment and prevention of pruritus | Astion Development A/S (DK) | 2006-10-04 | — | — | EP | claimed |
| EP-1707201-A1 | Oxaprozin or a closely related compound for the treatment of eczema | Astion Development A/S (DK) | 2006-10-04 | — | — | EP | claimed |
| US-20060251689-A1 | Treatment or prevention of pruritus | ASTION DEVELOPMENT A/S | 2006-11-09 | — | — | US | disclosed |
| US-20060229347-A1 | Treatment of eczemas | ASTION DEVELOPMENT A/S | 2006-10-12 | — | — | US | disclosed |
| WO-2006102898-A2 | OXAPROZIN OR A CLOSELY RELATED COMPOUND FOR THE TREATMENT OF ECZEMA | ASTION PHARMA A/S (DK) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006102900-A1 | DERMATOLOGICAL COMPOSITIONS AND SALTS FOR THE TREATMENT OF DERMATOLOGICAL DISEASES | ASTION PHARMA A/S (DK) | 2006-10-05 | — | — | WO | disclosed |
| US-20060222671-A1 | Dermatological compositions and salts for the treatment of dermatological diseases | ASTION DEVELOPMENT A/S | 2006-10-05 | — | — | US | disclosed |
| EP-0699192-B1 | SUBSTITUTED OXAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 2002-07-24 | — | — | EP | disclosed |
| US-6090834-A | ANALGESICS; RHEUMATIC DISORDERS; SKIN DISORDERS; GASTROINTESTINAL DISORDERS | G.D. SEARLE & CO. (US) | 2000-07-18 | — | — | US | disclosed |
| EP-0825989-A1 | SUBSTITUTED OXAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1998-03-04 | — | — | EP | disclosed |
| WO-1996036617-A1 | SUBSTITUTED OXAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-11-21 | — | — | WO | disclosed |
| EP-0699192-A1 | SUBSTITUTED OXAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-03-06 | — | — | EP | disclosed |
| WO-1994027980-A1 | SUBSTITUTED OXAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1994-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229347-A1 | Treatment of eczemas | ZAP70, SYK, LCK | RXRA 3666/4885RXRB 3539/4885RXRG 3772/4885 |
| US-20060251689-A1 | Treatment or prevention of pruritus | ITCH, TSLP, HRH4 | RXRA 2936/4885RXRB 3360/4885RXRG 3484/4885 |
| US-20060222671-A1 | Dermatological compositions and salts for the treatment of dermatological diseases | ZAP70, SYK, LCK | RXRA 4453/4885RXRB 4463/4885RXRG 4547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.